By Professor Michael Leonard Friedlander

Journal articles

Inglis H; Boyle FM; Friedlander ML; Watson SL, 2015, 'Dry eyes and AIs: If you don't ask you won't find out', Breast, 24, pp. 694 - 698, http://dx.doi.org/10.1016/j.breast.2015.08.008

Lee CK; Lord S; Grunewald T; Gebski V; Hardy-Bessard AC; Sehouli J; Woie K; Heywood M; Schauer C; Vergote I; Scambia G; Ferrero A; Harter P; Pujade-Lauraine E; Friedlander M, 2015, 'Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: Analysis of the CALYPSO trial', Gynecologic Oncology, 136, pp. 18 - 24, http://dx.doi.org/10.1016/j.ygyno.2014.09.017

Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RHJ; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M, 2015, 'Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: A randomised phase 2 trial', The Lancet Oncology, 16, pp. 87 - 97, http://dx.doi.org/10.1016/S1470-2045(14)71135-0

Ledermann J; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott CL; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Dougherty B; Orr M; Hodgson D; Barrett JC; Matulonis U, 2015, 'Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial', Obstetrical and Gynecological Survey, 69, pp. 594 - 596, http://dx.doi.org/10.1097/ogx.0000000000000107

Wilson MK; Collyar D; Chingos DT; Friedlander M; Ho TW; Karakasis K; Kaye S; Parmar MKB; Sydes MR; Tannock IF; Oza AM, 2015, 'Outcomes and endpoints in cancer trials: Bridging the divide', The Lancet Oncology, 16, pp. e43 - e52, http://dx.doi.org/10.1016/S1470-2045(14)70380-8

Floquet A; Vergote I; Colombo N; Fiane B; Monk BJ; Reinthaller A; Calvert P; Herzog TJ; Meier W; Kim JW; Campo JMD; Friedlander M; Pisano C; Isonishin S; Crescenzo RJ; Barrett C; Wang K; Mitrica I; Bois AD, 2015, 'Progression-free survival by local investigator versus independent central review: Comparative analysis of the AGO-OVAR16 Trial', Gynecologic Oncology, 136, pp. 37 - 42, http://dx.doi.org/10.1016/j.ygyno.2014.11.074

Park SB; Kwok JB; Loy CT; Friedlander ML; Lin CSY; Krishnan AV; Lewis CR; Kiernan MC; Goldstein D, 2014, 'Paclitaxel-induced neuropathy: Potential association of MAPT and GSK3B genotypes', BMC Cancer, 14, pp. 993, http://dx.doi.org/10.1186/1471-2407-14-993

Bock VL; Friedlander M; Waring D; Kossard S; Wood GK, 2014, 'Cutaneous adverse effects of hormonal adjuvant therapy for breast cancer: A case of localised urticarial vasculitis following anastrozole therapy and a review of the literature', Australasian Journal of Dermatology, 55, pp. 282 - 285, http://dx.doi.org/10.1111/ajd.12110

Reed NS; Gomez-Garcia E; Gallardo-Rincon D; Barrette B; Baumann K; Friedlander M; Kichenadasse G; Kim JW; Lorusso D; Mirza MR; Ray-Coquard I, 2014, 'Gynecologic cancer InterGroup (GCIG) consensus review for carcinoid tumors of the ovary', International Journal of Gynecological Cancer, 24, pp. S35 - S41, http://dx.doi.org/10.1097/IGC.0000000000000265

Hasegawa K; Nagao S; Yasuda M; Millan D; Viswanathan AN; Glasspool RM; Devouassoux-Shisheboran M; Covens A; Lorusso D; Kurzeder C; Kim JW; Gladieff L; Bryce J; Friedlander M; Fujiwara K, 2014, 'Gynecologic cancer intergroup (GCIG) consensus review for clear cell carcinoma of the uterine corpus and cervix', International Journal of Gynecological Cancer, 24, pp. S90 - S95, http://dx.doi.org/10.1097/IGC.0000000000000297

Amant F; Floquet A; Friedlander M; Kristensen G; Mahner S; Nam EJ; Powell MA; Ray-Coquard I; Siddiqui N; Sykes P; Westermann AM; Seddon B, 2014, 'Gynecologic Cancer InterGroup (GCIG) Consensus Review for Endometrial Stromal Sarcoma', International Journal of Gynecological Cancer, 24, pp. S67 - S72, http://dx.doi.org/10.1097/IGC.0000000000000205

Ledermann JA; Luvero D; Shafer A; O'Connor D; Mangili G; Friedlander M; Pfisterer J; Mirza MR; Kim JW; Alexandre J; Oza A; Brown J, 2014, 'Gynecologic cancer intergroup (GCIG) Consensus review for mucinous ovarian carcinoma', International Journal of Gynecological Cancer, 24, pp. S14 - S19, http://dx.doi.org/10.1097/IGC.0000000000000296

Friedlander ML; Covens A; Glasspool RM; Hilpert F; Kristensen G; Kwon S; Selle F; Small W; Witteveen E; Russell P, 2014, 'Gynecologic cancer intergroup (GCIG) consensus review for mullerian adenosarcoma of the female genital tract', International Journal of Gynecological Cancer, 24, pp. S78 - S82, http://dx.doi.org/10.1097/IGC.0000000000000239

Brown J; Friedlander M; Backes FJ; Harter P; O'Connor DM; De La Motte Rouge T; Lorusso D; Maenpaa J; Kim JW; Tenney ME; Seckl MJ, 2014, 'Gynecologic cancer intergroup (GCIG) consensus review for ovarian germ cell tumors', International Journal of Gynecological Cancer, 24, pp. S48 - S54, http://dx.doi.org/10.1097/IGC.0000000000000223

Reed NS; Pautier P; Åvall-Lundqvist E; Choi CH; Du Bois A; Friedlander M; Fyles A; Kichenadasse G; Provencher DM; Ray-Coquard I, 2014, 'Gynecologic cancer interGroup (GCIG) consensus review for ovarian small cell cancers', International Journal of Gynecological Cancer, 24, pp. S30 - S34, http://dx.doi.org/10.1097/IGC.0000000000000293

Webber K; Sommeijer D; Mileshkin L; Friedlander ML, 2014, 'OVQUEST: LIVING AFTER THE DIAGNOSIS AND TREATMENT OF OVARIAN CANCER. PRELIMINARY RESULTS FROM AN INTERNET-BASED SURVEY', INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 24, pp. 252 - 252, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344966500197&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Sousa M; Meiser B; Hickey M; Jarvis S; Lombard J; Chirgwin J; Segelov E; Lewis C; Friedlander M, 2014, 'PEGASUS - PREVALENCE AND SEVERITY OF GENITOURINARY SYMPTOMS AND IMPACT ON SEXUAL FUNCTION AND QOL IN POSTMENOPAUSAL WOMEN RECEIVING ENDOCRINE THERAPY FOR EARLY BREAST CANCER', INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 24, pp. 1041 - 1042, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344966501317&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Joly F; McAlpine J; Nout R; Åvall-Lundqvist E; Shash E; Friedlander M, 2014, 'Quality of life and patient-reported outcomes in endometrial cancer clinical trials: A call for action!', International Journal of Gynecological Cancer, 24, pp. 1693 - 1699, http://dx.doi.org/10.1097/IGC.0000000000000299

McAlpine JN; Greimel E; Brotto LA; Nout RA; Shash E; Åvall-Lundqvist E; Friedlander ML; Joly F, 2014, 'Quality of life research in endometrial cancer what is needed to advance progress in this disease site? Methodological considerations from the Gynecologic cancer InterGroup Symptom Benefit Working Group brainstorming session, leiden 2012', International Journal of Gynecological Cancer, 24, pp. 1686 - 1692, http://dx.doi.org/10.1097/IGC.0000000000000245

Du Bois A; Floquet A; Kim JW; Rau J; Del Campo JM; Friedlander M; Pignata S; Fujiwara K; Vergote I; Colombo N; Mirza MR; Monk BJ; Kimmig R; Ray-Coquard I; Zang R; Diaz-Padilla I; Baumann KH; Mouret-Reynier MA; Kim JH; Kurzeder C; Lesoin A; Vasey P; Marth C; Canzler U; Scambia G; Shimada M; Calvert P; Pujade-Lauraine E; Kim BG; Herzog TJ; Mitrica I; Schade-Brittinger C; Wang Q; Crescenzo R; Harter P, 2014, 'Incorporation of pazopanib in maintenance therapy of ovarian cancer', Journal of Clinical Oncology, 32, pp. 3374 - 3381, http://dx.doi.org/10.1200/JCO.2014.55.7348

Harter P; du Bois A; WImberger P; Schmalfeldt B; Emons G; Kreienberg R; Hilpert F; Lück HJ; Matulonis U; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Mapherson E; Dougherty B; Juergensmeier JM; Orr M; Ledermann J, 2014, 'Erhaltungstherapie mit Olaparib nach platinhaltiger Re-induktion bei platinsensitivem serösem Ovarialkarzinomrezidiv: eine Placebo-kontrollierte Phase II Studie', Geburtshilfe und Frauenheilkunde, 74, http://dx.doi.org/10.1055/s-0034-1388545

Anuradha S; Webb PM; Blomfield P; Brand AH; Friedlander M; Leung Y; Obermair A; Oehler MK; Quinn M; Steer C; Jordan SJ, 2014, 'Survival of Australian women with invasive epithelial ovarian cancer: A populationbased study', Medical Journal of Australia, 201, pp. 283 - 288, http://dx.doi.org/10.5694/mja14.00132

Meiser B; Price MA; Butow PN; Rahman B; Tucker K; Cheah B; Bickerstaffe A; Hopper J; Phillips KA; Bennett B; Tennant C; Milne RL; Weideman P; Stanhope L; Picken S; Friedlander ML; Goldgar D, 2014, 'Misperceptions of ovarian cancer risk in women at increased risk for hereditary ovarian cancer', Familial Cancer, 13, pp. 153 - 162, http://dx.doi.org/10.1007/s10689-013-9687-y

Mileshkin LR; Narayan K; Moore KN; Rischin D; King M; Kolodziej I; Martyn J; Friedlander M; Quinn M; Small W; Thomas G; Fyles AW; Gebski V; Stockler MR, 2014, 'A phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: Outback (ANZGOG0902/GOG0274/RTOG1174).', Journal of Clinical Oncology, 32, pp. TPS5632 - TPS5632, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.tps5632

Gao B; Russell A; Beesley J; Chen XQ; Healey S; Henderson M; Wong M; Emmanuel C; Galletta L; Johnatty SE; Bowtell D; Haber M; Norris M; Harnett P; Chenevix-Trench G; Balleine RL; Defazio A; Gertig D; Green A; Webb P; Hung J; Moore S; Traficante N; Fereday S; Harrap K; Sadkowsky T; Pandeya N; Stuart-Harris R; Kirsten F; Rutovitz J; Clingan P; Glasgow A; Proietto A; Braye S; Otton G; Shannon J; Bonaventura T; Stewart J; Begbie S; Friedlander M; Bell D; Baron-Hay S; Ferrier A; Gard G; Nevell D; Pavlakis N; Valmadre S; Young B; Camaris C; Crouch R; Edwards L; Hacker N; Marsden D; Robertson G; Beale P; Beith J; Carter J; Dalrymple C; Hamilton A; Houghton R; Russell P; Links M; Grygiel J; Hill J; Brand A; Byth K; Jaworski R; Sharma R; Achen A; Wain G; Ward B; Papadimos D; Crandon A; Cummings M; Horwood K; Obermair A; Perrin L; Wyld D; Nicklin J; Davy M; Oehler MK; Hall C; Dodd T; Healy T; Pittman K; Henderson D; Miller J; Pierdes J; Blomfield P; Challis D; McIntosh R; Parker A; Brown B; Rome R; Allen D; Grant P; Hyde S; Laurie R; Robbie M; Healy D; Underhill C, 2014, 'Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer', Scientific Reports, 4, pp. 4669, http://dx.doi.org/10.1038/srep04669

Stockler MR; Hilpert F; Friedlander M; King MT; Wenzel L; Lee CK; Joly F; De Gregorio N; Arranz JA; Mirza MR; Sorio R; Freudensprung U; Sneller V; Hales G; Pujade-Lauraine E, 2014, 'Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer', Journal of Clinical Oncology, 32, pp. 1309 - 1316, http://dx.doi.org/10.1200/JCO.2013.51.4240

Davis A; Tinker AV; Friedlander M, 2014, '"platinum resistant" ovarian cancer: What is it, who to treat and how to measure benefit?', Gynecologic Oncology, 133, pp. 624 - 631, http://dx.doi.org/10.1016/j.ygyno.2014.02.038

Grimison PS; Stockler MR; Chatfield M; Thomson DB; Gebski V; Friedlander M; Boland AL; Houghton B; Gurney H; Rosenthal M; Singhal N; Kichenadasse G; Wong SS; Lewis CR; Vasey PA; Toner GC, 2014, 'Accelerated BEP for metastatic germ cell tumours: a multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)', Annals of Oncology, 25, pp. 143 - 148, http://dx.doi.org/10.1093/annonc/mdt369

Butow PN; Price MA; Bell ML; Webb PM; Defazio A; Friedlander M, 2014, 'Caring for women with ovarian cancer in the last year of life: A longitudinal study of caregiver quality of life, distress and unmet needs', Gynecologic Oncology, 132, pp. 690 - 697, http://dx.doi.org/10.1016/j.ygyno.2014.01.002

Friedlander ML, 2014, 'Commentary on the clinical trial reported by: Tewari KS, Sill M, Long III HJ, et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: A phase III randomized trial of the Gynecologic Oncology Group. J Clin Oncol 2013;(suppl; abstr 3)', Chinese Clinical Oncology, 3, http://dx.doi.org/10.3978/j.issn.2304-3865.2013.11.01

King MT; Stockler MR; Butow P; O'Connell R; Voysey M; Oza AM; Gillies K; Donovan HS; Mercieca-Bebber R; Martyn J; Sjoquist K; Friedlander ML, 2014, 'Development of the measure of ovarian symptoms and Treatment concerns aiming for optimal measurement of patient-reported symptom benefit with chemotherapy for symptomatic ovarian cancer', International Journal of Gynecological Cancer, 24, pp. 865 - 873, http://dx.doi.org/10.1097/IGC.0000000000000167

Ledermann J; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott CL; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Dougherty B; Orr M; Hodgson D; Barrett JC; Matulonis U, 2014, 'Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial', The Lancet Oncology, 15, pp. 852 - 861, http://dx.doi.org/10.1016/S1470-2045(14)70228-1

Friedlander ML; Stockler M; O'Connell R; Voysey M; Oza A; Gillies K; Donovan H; Martyn J; Sjoquist K; Butow P; King MT, 2014, 'Symptom burden and outcomes of patients with platinum resistant/refractory recurrent ovarian cancer a reality check: Results of stage 1 of the gynecologic cancer intergroup symptom benefit study', International Journal of Gynecological Cancer, 24, pp. 857 - 864, http://dx.doi.org/10.1097/IGC.0000000000000147

Murray JE; Pickering HR; Lin CS-Y; Goldstein D; Friedlander ML; Kiernan MC; Krishnan AV, 2014, '6. Functional impact of neuropathy in patients receiving oxaliplatin chemotherapy', Clinical Neurophysiology, 125, pp. e3 - e3, http://dx.doi.org/10.1016/j.clinph.2013.10.028

Matulonis UA; Harter P; Gourley C; Friedlander M; Vergote IB; Rustin GJS; Fielding A; Spencer S; Ho TW; Ledermann JA, 2014, 'Analysis of intermediate clinical endpoints from a Phase II trial of olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC)', Gynecologic Oncology, 133, pp. 54 - 55, http://dx.doi.org/10.1016/j.ygyno.2014.03.152

Long A; Toner G; Stockler MR; Thomson DB; Gebski V; Yip S; King M; Friedlander M; Quinn DI; Singhal N; Roncolato F; Grimison P, 2014, 'Anzup 1302: a Randomised Phase 3 Trial of Accelerated Versus Standard Bep Chemotherapy for Patients with Intermediate and Poor-Risk Metastatic Germ Cell Tumours (P3Bep)', Annals of Oncology, 25, pp. iv303 - iv303, http://dx.doi.org/10.1093/annonc/mdu337.65

Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote IB; Rustin GJS; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei DE; Fielding A; Spencer S; Bennett B; Parry D; Matulonis U, 2014, 'Health-Related Quality of Life (Hrqol) During Olaparib Maintenance Therapy in Patients with Platinum-Sensitive Relapsed Serous Ovarian Cancer (Psr Soc) and a Brca Mutation (Brcam)', Annals of Oncology, 25, pp. iv308 - iv308, http://dx.doi.org/10.1093/annonc/mdu338.11

Nomura H; Hanker L; Fabbro M; Rau J; Kim Y; Arija JAA; Friedlander M; Ferrandina G; Vuylsteke P; Colombo N; Malander S; Monk BJ; Petru E; Calvert P; Herzog T; Barrett C; Jobanputra M; Wang Q; Elser G; Du Bois A, 2014, 'Pazopanib Versus Placebo in Women Without Progression After First-Line Chemotherapy for Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (Aeoc): Second Interim Overall Survival Analysis from the Ago-Ovar16 Trial', Annals of Oncology, 25, pp. iv307 - iv307, http://dx.doi.org/10.1093/annonc/mdu338.6

Peculis LD; Ius Y; Campion M; Friedlander M; Hacker N, 2014, 'Stage IB2 adenosquamous cervical cancer diagnosed at 19-weeks gestation', Australian and New Zealand Journal of Obstetrics and Gynaecology, http://dx.doi.org/10.1111/ajo.12281

Sommeijer DW; Sjoquist KM; Friedlander M, 2013, 'Hormonal treatment in recurrent and metastatic gynaecological cancers: A review of the current literature', Current Oncology Reports, 15, pp. 541 - 548, http://dx.doi.org/10.1007/s11912-013-0343-3

Thewes B; Bell ML; Butow P; Beith J; Boyle F; Friedlander M; McLachlan SA, 2013, 'Psychological morbidity and stress but not social factors influence level of fear of cancer recurrence in young women with early breast cancer: Results of a cross-sectional study', Psycho-Oncology, 22, pp. 2797 - 2806, http://dx.doi.org/10.1002/pon.3348

Sjoquist KM; Friedlander ML; O'Connell RL; Voysey M; King MT; Stockler MR; Oza AM; Gillies K; Martyn JK; Butow PN, 2013, 'Hope, quality of life, and benefit from treatment in women having chemotherapy for platinum-resistant/refractory recurrent ovarian cancer: The gynecologic cancer intergroup symptom benefit study', Oncologist, 18, pp. 1221 - 1228, http://dx.doi.org/10.1634/theoncologist.2013-0175

Park SB; Goldstein D; Krishnan AV; Lin CSY; Friedlander ML; Cassidy J; Koltzenburg M; Kiernan MC, 2013, 'Chemotherapy-induced peripheral neurotoxicity: A critical analysis', CA Cancer Journal for Clinicians, http://dx.doi.org/10.1002/caac.21204

Collins IM; Milne RL; McLachlan SA; Friedlander M; Hickey M; Weideman PC; Birch KE; Hopper JL; Phillips KA, 2013, 'Do BRCA1 and BRCA2 mutation carriers have earlier natural menopause than their noncarrier relatives? Results from the Kathleen Cuningham foundation consortium for research into familial breast cancer', Journal of Clinical Oncology, 31, pp. 3920 - 3925, http://dx.doi.org/10.1200/JCO.2013.49.3007

Collins IM; Milne RL; Weideman PC; McLachlan SA; Friedlander ML; Cuningham K; Hopper JL; Phillips KA, 2013, 'Preventing breast and ovarian cancers in high-risk BRCA1 and BRCA2 mutation carriers', Medical Journal of Australia, 199, pp. 680 - 683, http://dx.doi.org/10.5694/mja13.10848

Price MA; Butow PN; Bell ML; Webb PM; deFazio A; Friedlander M; Fardell JE, 2013, 'PSYCHOSOCIAL PREDICTORS OF SURVIVAL IN WOMEN WITH INVASIVE OVARIAN CANCER: A POPULATION-BASED PROSPECTIVE STUDY', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 9, pp. 91 - 91, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000325868800106&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Ang JE; Gourley C; Powell CB; High H; Shapira-Frommer R; Castonguay V; De Greve J; Atkinson T; Yap TA; Sandhu S; Banerjee S; Chen LM; Friedlander ML; Kaufman B; Oza AM; Matulonis U; Barber LJ; Kozarewa I; Fenwick K; Assiotis I; Campbell J; Chen L; De Bono JS; Gore ME; Lord CJ; Ashworth A; Kaye SB, 2013, 'Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: A multi-institutional study', Clinical Cancer Research, 19, pp. 5485 - 5493, http://dx.doi.org/10.1158/1078-0432.CCR-13-1262

Blinman P; Gainford C; Donoghoe M; Martyn J; Blomfield P; Grant P; Kichenadasse G; Vaughan M; Brand A; Shannon C; Gebski V; Stockler M; Friedlander M, 2013, 'Feasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: An ANZGOG study', Journal of Gynecologic Oncology, 24, pp. 359 - 366, http://dx.doi.org/10.3802/jgo.2013.24.4.359

Phillips KA; Milne RL; Rookus MA; Daly MB; Antoniou AC; Peock S; Frost D; Easton DF; Ellis S; Friedlander ML; Buys SS; Andrieu N; Noguès C; Stoppa-Lyonnet D; Bonadona V; Pujol P; McLachlan SA; John EM; Hooning MJ; Seynaeve C; Tollenaar RAEM; Goldgar DE; Terry MB; Caldes T; Weideman PC; Andrulis IL; Singer CF; Birch K; Simard J; Southey MC; Olsson HL; Jakubowska A; Olah E; Gerdes AM; Foretova L; Hopper JL, 2013, 'Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers', Journal of Clinical Oncology, 31, pp. 3091 - 3099, http://dx.doi.org/10.1200/JCO.2012.47.8313

Price MA; Bell ML; Sommeijer DW; Friedlander M; Stockler MR; Defazio A; Webb PM; Butow PN, 2013, 'Physical symptoms, coping styles and quality of life in recurrent ovarian cancer: A prospective population-based study over the last year of life', Gynecologic Oncology, 130, pp. 162 - 168, http://dx.doi.org/10.1016/j.ygyno.2013.03.031

Back to profile page